Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.
Balgos A, Hannawi S, Chen WL, Abuquta A, Safeldin L, Hassan A, Alamadi A, Tirador L, Jaen AM, Villalobos RE, Mo C, Yue ZJ, Ma Y, Wang QS, Wen RD, Yao Z, Yu JP, Yao WR, Zhang JH, Hong KX, Liu Y, Li JX. Balgos A, et al. Among authors: safeldin l. Expert Rev Vaccines. 2024 Jan-Dec;23(1):419-431. doi: 10.1080/14760584.2024.2334423. Epub 2024 Apr 2. Expert Rev Vaccines. 2024. PMID: 38529685 Free article. Clinical Trial.
Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open-label, and single-arm Phase 1 study.
Hannawi S, Zhang RR, Abuquta A, Safeldin L, Hassan A, Alamadi A, Hossain T, Mostafa M, Ghoneim Y, Solo J, Zheng HX, Wu DF, Yu DD, Yuan JC, Zhao D, Lin R, Ying B, Qin CF. Hannawi S, et al. Among authors: safeldin l. Clin Transl Med. 2023 Aug;13(8):e1387. doi: 10.1002/ctm2.1387. Clin Transl Med. 2023. PMID: 37612802 Free PMC article. Clinical Trial. No abstract available.